Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Bluebird Bio
Bluebird Bio
Bluebird bio lays off staffers in Europe as Zynteglo rollout hits an early reimbursement snag
Bluebird bio lays off staffers in Europe as Zynteglo rollout hits an early reimbursement snag
Fierce Pharma
Bluebird Bio
Zynteglo
reimbursement
layoffs
Germany
gene therapy
Flag link:
Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors
Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors
Fierce Biotech
Bluebird Bio
PsiOxus
CAR-T
solid tumors
Flag link:
New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds
New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds
BioPharma Dive
Bristol Myers Squibb
Bluebird Bio
ICER
Multiple Myeloma
CAR-T
Flag link:
Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts
Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts
Fierce Pharma
Bristol Myers Squibb
Bluebird Bio
CAR-T
JNJ
Legend Biotech
Abecma
Flag link:
FDA approves first CAR-T cell therapy for multiple myeloma
FDA approves first CAR-T cell therapy for multiple myeloma
BioPharma Dive
Bristol-Myers Squibb
Bluebird Bio
CAR-T
Multiple Myeloma
Abecma
FDA
Flag link:
Bluebird bio CMO quits amid a roller coaster year and upcoming split
Bluebird bio CMO quits amid a roller coaster year and upcoming split
Fierce Biotech
Bluebird Bio
Flag link:
Blown off course, Bluebird shares tick up on positive gene therapy readout
Blown off course, Bluebird shares tick up on positive gene therapy readout
Fierce Biotech
Bluebird Bio
cALD
gene therapy
FDA
Flag link:
EMA begins safety review of bluebird gene therapy following AML case in related therapy
EMA begins safety review of bluebird gene therapy following AML case in related therapy
Endpoints
Bluebird Bio
Zynteglo
Europe
EMA
AML
Flag link:
Bluebird seeks gene therapy trial restart after cancer scare
Bluebird seeks gene therapy trial restart after cancer scare
Pharmaforum
Bluebird Bio
LentiGlobin
gene therapy
sickle cell disease
AML
Flag link:
Bluebird’s Zynteglo safety snag could spell trouble for other gene therapies: analysts
Bluebird’s Zynteglo safety snag could spell trouble for other gene therapies: analysts
Fierce Pharma
gene therapy
Bluebird Bio
Zynteglo
clinical trials
Flag link:
Bluebird stops studies of sickle cell gene therapy after new cancer cases
Bluebird stops studies of sickle cell gene therapy after new cancer cases
BioPharma Dive
Bluebird Bio
gene therapy
sickle cell disease
leukemia
clinical trials
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
JPM: Bluebird to spin off cancer therapies into new company
JPM: Bluebird to spin off cancer therapies into new company
Fierce Biotech
Bluebird Bio
spinoffs
oncology
JPMHC 2021
Oncology Newco
Flag link:
10 Biopharma Stories to Look Forward to in 2021
10 Biopharma Stories to Look Forward to in 2021
BioSpace
pandemic
COVID-19
vaccines
Joe Biden
drug pricing
M&A
venture capital
JNJ
Biomarin
Bluebird Bio
TG Therapeutics
Biogen
AstraZeneca
Flag link:
3 FDA Dates Biotech Investors Should Circle in 2021
3 FDA Dates Biotech Investors Should Circle in 2021
Motley Fool
FDA
biotech
Bluebird Bio
ide-cel
Multiple Myeloma
Biogen
aducanumab
Alzheimer's disease
targeted therapeutics
umbralisib
maringal zone lymphoma
Flag link:
Bluebird trumpets long-term data from beta-thalassaemia gene therapy
Bluebird trumpets long-term data from beta-thalassaemia gene therapy
Pharmaforum
Bluebird Bio
Zinteglo
gene therapy
beta-thalassemia
Flag link:
FDA gene therapy holdups suggest closer scrutiny by agency
FDA gene therapy holdups suggest closer scrutiny by agency
BioPharma Dive
FDA
gene therapy
Sarepta Therapeutics
Voyager Therapeutics
Iovance
Bluebird Bio
Flag link:
Can bluebird bio Recover From Another Major Setback?
Can bluebird bio Recover From Another Major Setback?
Motley Fool
Bluebird Bio
bb1111
sickle cell disease
Flag link:
FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay
FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay
Endpoints
Bluebird Bio
FDA
sickle cell disease
gene therapy
HGB-206
Flag link:
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Fierce Biotech
Bristol-Myers Squibb
Celgene
Bluebird Bio
FDA
priority review
ide-cel
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »